Compliance with guideline-directed basic pharmacotherapy and late adverse events in patients with stable coronary artery disease after isolated surgical revascularization

Abstract Background Long-term basic pharmacotherapy may have a major impact upon clinical course and survival in patients with stable coronary artery diseases (CAD) after isolated coronary artery bypass grafting (CABG). Purpose To determine the role of compliance with guideline-directed basic pharma...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal 2020-11, Vol.41 (Supplement_2)
Main Authors: Yepanchintseva, O, Mikhaliev, K, Shklianka, I, Zharinov, O, Todurov, B
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Long-term basic pharmacotherapy may have a major impact upon clinical course and survival in patients with stable coronary artery diseases (CAD) after isolated coronary artery bypass grafting (CABG). Purpose To determine the role of compliance with guideline-directed basic pharmacotherapy in the prevention of late major adverse clinical events (MAEs) in patients with stable CAD after isolated CABG at 3-year follow-up. Methods A single-centre study included 576 patients with stable CAD, consecutively enrolled for isolated CABG during the period 2011–2017. Follow-up median was 34 months (interquartile range 13–60 months). Two (0.3%) patients died early after CABG, thus 574 (99.7%) patients were followed post-discharge. At 3-year follow-up, data on MAEs were available in 251 patients, mean age (61±9) years, 218 (86.9%) males. Among them, MAEs occurred in 55 (21.9%) cases. Results Basic CAD pharmacotherapy after CABG was comparable in MAEs vs. no-MAEs groups, with the vast majority of patients receiving guideline-recommended therapy at discharge, namely angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-II receptors blockers (ARBs) (79.6% vs. 88.8%, respectively; p=0.109), statins (98.1% vs. 99.0%, respectively; p=0.619) and antiplatelet drugs (98.1% vs. 99.5%, respectively; p=0.327). At 3-year follow-up, MAEs group, as opposed to no-MAEs group, was characterized by the lower usage of ACEI/ARBs (68.5% vs. 87.2%, respectively; p=0.001) and statins (59.3% vs. 86.7%, respectively; p
ISSN:0195-668X
1522-9645
DOI:10.1093/ehjci/ehaa946.1459